RZRuiyi Zhou

Ruiyi Zhou

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ruiyi Zhou has a total of 24 co-authors. Here are the top co-authors by number of shared publications:

  • Runhui Liu

    East China University of Science and Technology

    3 shared publications
  • Kang Chen

    Key Laboratory for Ultrafine Materials of Ministry of Education Frontiers Science Center for Materiobiology and Dynamic Chemistry Research Center for Biomedical Materials of Ministry of Education East China University of Science and Technology Shanghai 200237 China

    2 shared publications
  • Min Zhou

    State Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai, China

    2 shared publications
  • Yueming Wu

    State Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai, China

    2 shared publications
  • Changyou Gao

    Zhejiang University

    1 shared publication
  • Deteng Zhang

    China Uruguay Bio-Nano Pharmaceutical Joint Laboratory, Cancer Institute, The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao Cancer Institute, Qingdao, Shandong Province, China

    1 shared publication

Latest Publications

  • A Polymeric Strategy Empowering Vascular Cell Selectivity and Potential Application Superior to Extracellular Matrix Peptides

    by Ruiyi Zhou, Yueming Wu, Kang Chen, Deteng Zhang, Qi Chen, Donghui Zhang, Yunrui She, Wenjing Zhang, Longqiang Liu, Yueqi Zhu, et al.

    Endothelialization of vascular implants plays a vital role in maintaining the long‐term vascular patency. In situ endothelialization and re‐endothelialization is generally achieved by selectively promoting endothelial cell (EC) adhesion and, meanwhile, suppressing smooth muscle cell (SMC) adhesion. Currently, such EC versus SMC selectivity is achieved and extensively used in vascular‐related biomaterials utilizing extracellular‐matrix‐derived EC‐selective peptides, dominantly REDV and YIGSR. Nevertheless, the application of EC‐selective peptides is limited due to their easy proteolysis, time‐consuming synthesis, and expensiveness. To address these limitations, a polymeric strategy in designing and finding EC‐selective biomaterials using amphiphilic β‐peptide polymers by tuning serum protein adsorption is reported. The optimal β‐peptide polymer displays EC versus SMC selectivity even superior to EC‐selective REDV peptide regarding cell adhesion, proliferation, and migration of ECs versus SMCs. Study of the mechanism indicates that surface adsorption of bovine serum albumin, an abundant and anti‐adhesive serum protein, plays a critical role in the ECs versus SMCs selectivity of β‐peptide polymer. In addition, surface modification of the optimal β‐peptide polymer effectively promotes the endothelialization of vascular implants and inhibits intimal hyperplasia. This study provides an alternative strategy in designing and finding EC‐selective biomaterials, implying great potential in the vascular‐related biomaterial study and application.


  • Facile synthesis of polypeptoids bearing bulky sidechains via urea accelerated ring-opening polymerization of α-amino acid N -substituted N -carboxyanhydrides

    by Kang Chen, Yueming Wu, Xue Wu, Min Zhou, Ruiyi Zhou, Jiangzhou Wang, Ximian Xiao, Yuan Yuan, Runhui Liu

    The organocatalyst 1,3-bis[3,5-bis(trifluoromethyl)phenyl]urea (U–O) accelerates the ring-opening polymerization of α-amino acid N -substituted N -carboxyanhydrides (NNCAs) for the rapid synthesis of polypeptoids bearing bulky sidechains.


  • Practical Preparation of Infection-Resistant Biomedical Surfaces from Antimicrobial β-Peptide Polymers

    by Fan Qi, Yuxin Qian, Ning Shao, Ruiyi Zhou, Si Zhang, Ziyi Lu, Min Zhou, Jiayang Xie, Ting Wei, Qian Yu, et al.

    Tackling microbial infection associated with biomaterial surfaces has been an urgent need. Synthetic β-peptide polymers can mimic host defense peptides (HDPs) and have potent antimicrobial activities without driving the bacteria to develop antimicrobial resistance. Herein, we demonstrate a plasma surface activation based practical β-peptide polymer modification to prepare antimicrobial surfaces for biomedical materials such as thermoplastic polyurethane (TPU), polytetrafluoroethylene (PTFE), polyvinyl pyrrolidone (PVP), polyvinyl chloride (PVC) and polydimethylsiloxane (PDMS). The β-peptide polymer-modified surfaces demonstrated effective killing on drug-resistant Gram-positive and Gram-negative bacteria. The antibacterial function retained completely even after the β-peptide polymer-modified surfaces were stored at ambient temperature for at least two months. Moreover, the optimum β-peptide polymer (50:50 DM:Hex) modified surfaces displayed no hemolysis and cytotoxicity. In vivo study using methicillin-resistant Staphylococcus aureus (MRSA) pre-incubated TPU-50:50 DM:Hex surfaces for subcutaneous implantation revealed a 2.4-log reduction of MRSA cells at the surrounding tissue of implanted TPU sheet and a significant suppression of infection, compared to bare TPU control. These results imply promising and practical applications of β-peptide polymer tethering to prepare infection-resistant surfaces for biomedical materials and devices.